CJC-1295 DAC
A long-acting synthetic analogue of GHRH incorporating Drug Affinity Complex (DAC) technology. The DAC modification enables covalent binding to serum albumin, dramatically extending biological half-life to 6–8 days. Critical research tool for studying sustained GH axis stimulation.
Research Use Only. CJC-1295 DAC is sold exclusively for in vitro research and laboratory use by qualified scientists. Not for human consumption, veterinary use, or clinical administration.
Research Literature
Published Research
CJC-1295 DAC is a long-acting GHRH analogue with albumin-binding DAC technology extending half-life to 6-8 days.
CJC-1295, a long-acting growth hormone-releasing hormone analog
Key finding: Single injection produces sustained GH and IGF-1 elevation lasting up to 6 days.
PubMed 16605282 ↗Prolonged GH elevation with CJC-1295 DAC
Key finding: DAC modification enables albumin binding, dramatically extending biological half-life.
PubMed 18682525 ↗GHRH analogues for GH deficiency research
Key finding: Long-acting GHRH analogues demonstrate superior IGF-1 normalization vs short-acting peptides.
PubMed 20463555 ↗Same Category